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Background: Little is known about modifiable behaviours that may be associated with epithelial ovarian cancer (EOC) survival. We
conducted a pooled analysis of 12 studies from the Ovarian Cancer Association Consortium to investigate the association
between pre-diagnostic physical inactivity and mortality.
Methods: Participants included 6806 women with a primary diagnosis of invasive EOC. In accordance with the Physical Activity
Guidelines for Americans, women reporting no regular, weekly recreational physical activity were classified as inactive. We utilised
Cox proportional hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) representing the associations
of inactivity with mortality censored at 5 years.
Results: In multivariate analysis, inactive women had significantly higher mortality risks, with (HR¼ 1.34, 95% CI: 1.18–1.52) and
without (HR¼ 1.22, 95% CI: 1.12–1.33) further adjustment for residual disease, respectively.
Conclusion: In this large pooled analysis, lack of recreational physical activity was associated with increased mortality among
women with invasive EOC.
Epithelial ovarian cancer (EOC) is the most deadly gynaecological
cancer in developed nations (Torre et al, 2015). Five-year survival
is approximately 46% in the United States and Europe (SEER,
2014; UK CR, 2015). Among women with invasive EOC, over 60%
are diagnosed with advanced-stage disease, with considerably
worse 5-year survival, ranging from 3 to 27% in the United States
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and the United Kingdom (SEER, 2014; UK CR, 2015). While
recent reports of improved long-term survival have been promising
(Akeson et al, 2009; Wright et al, 2015), most women diagnosed
with advanced-stage EOC will die from their disease, generally
within 5 years of diagnosis.
The most commonly cited prognostic factors associated with
invasive EOC survival are unmodifiable, and include disease stage
and grade at diagnosis, histology, and the extent of residual disease
remaining after tumour resection (Winter et al, 2007; Cress et al,
2015; Wright et al, 2015). While little is known about modifiable
behaviours that may be associated with EOC prognosis, the lack of
recreational physical activity, defined by the Physical Activity
Guidelines for Americans (PAGA) as engaging in no regular,
weekly, moderate-, or vigorous-intensity exercise during leisure
time (USDHHS, 2008), is a potentially modifiable behavioural
target for improving prognosis (Sanchis-Gomar et al, 2015; Li et al,
2016).
Worldwide, over 31% of adults are physically inactive, but
inactivity increases with age and is higher among women than men
(Hallal et al, 2012). As an exposure variable, inactivity can be
assessed with less misclassification than incremental categories of
physical activity (Bull et al, 2004; Celis-Morales et al, 2012).
Inactivity may also reflect physiological pathways that affect
carcinogenesis independently from pathways associated with
obesity or physical activity and skeletal muscle contraction
(Fiuza-Luces et al, 2013; Byers, 2014; Hildebrand et al, 2015;
Sanchis-Gomar et al, 2015). Few studies have systematically
evaluated the association between physical inactivity and ovarian
cancer prognosis. Thus, we chose to examine the association of
physical inactivity with subsequent mortality in women diagnosed
with invasive EOC.
MATERIALS AND METHODS
We conducted a pooled analysis utilising individual-level data from
12 studies in the Ovarian Cancer Association Consortium (OCAC)
(Berchuck et al, 2008). Study protocols were approved by the
respective institutional review boards, and participants provided
written informed consent. The study population included 6806
women aged 18 years and older, with histologically confirmed
primary diagnoses of invasive EOC, fallopian tube cancer, or
primary peritoneal cancer.
Analysis variables. Mortality was assessed with time-to-event
analyses censored at 5 years. Thus, women were followed from the
date of diagnosis to the earliest of date of death, date of last follow-
up, or 5 years after the date of diagnosis. Available covariates
included a comprehensive set of epidemiological and clinical
variables from the OCAC core data set, which was collated,
reviewed, cleaned, and harmonised for use in OCAC pooled
analyses.
Physical activity was assessed using self- or interviewer-
administered questionnaires. Questionnaire format for assessing
physical activity habits varied between studies, but all question-
naires allowed for the identification of inactive women as defined
by the PAGA. Women reporting no regular moderate- to vigorous-
intensity recreational physical activities were categorised as
inactive, our exposure of interest. Questionnaires from nine
studies (AUS, CON, DOV, HAW, MAL, NEC, NJO, USC, and
HOP; Table 1) yielded data reflecting pre-diagnostic activity
spanning the course of adulthood, while questionnaires from three
studies (JPN, MAY, and MAC; Table 1) yielded data reflecting
activity at enrollment. To reduce the likelihood of reverse causation
as an explanation for observed associations, we conducted
sensitivity analyses excluding the three studies assessing inactivity
at enrollment.
Statistical methods. Multivariable Cox proportional hazards
models were used to estimate hazard ratios (HRs) and 95%
confidence intervals (CIs) representing the association between
physical inactivity and mortality risk. We examined mortality
overall and according to subgroups by tumour histology, tumour
stage, menopausal status, and body mass index (BMI) classifica-
tion. We pre-specified age at diagnosis, tumour stage, and histology
as important adjustment variables; additional confounders were
identified utilising the 10% change-in-estimate guide (Maldonado
and Greenland, 1993). While the extent of residual disease after
surgical resection is a well-established prognostic factor for
invasive EOC, these data were only available in a subset of
participants (N¼ 2473). Therefore, we estimated the association
between inactivity and mortality through two multivariable
models, with and without adjustment for residual disease. Finally,
between-study heterogeneity for the association between inactivity
and mortality was assessed by means of Q-statistics (Po0.05) and
I-squared statistics (o50%) (Higgins et al, 2003).
RESULTS
During the follow-up period, 2935 participants (43.1%) died. All
but one study (MAC) included herein were case–control studies
and nine studies originated in the United States (Table 1).
Participants were mostly white, post-menopausal women with
advanced-stage high-grade serous EOC. Collectively, 24.5% of
participants self-reported inactivity before diagnosis (Supplementary
Table S1).
For the association of inactivity with mortality, we observed no
significant heterogeneity between studies (Q-statistic P¼ 0.21;
I-squared¼ 23.7%), nor evidence of a site-by-inactivity interaction
(P¼ 0.12). Therefore, we estimated pooled multivariable HRs and
95% CIs utilising a combined data set. Inactive women had
significantly greater risk of mortality (HR¼ 1.22, 95% CI: 1.12–
1.33) (Table 2); the association remained significant with
adjustment for residual disease (HR¼ 1.34, 95% CI: 1.18–1.52;
Table 3). Further control for smoking and BMI did not affect the
significant increased risk of mortality among inactive women with
(HR¼ 1.35, 95% CI: 1.16–1.56) or without (HR¼ 1.16, 95% CI:
1.05–1.27) adjustment for residual disease.
In subgroup analyses by histology, inactive women with high-
grade serous tumours had significantly higher mortality risks in
models without adjustment for residual disease (HR¼ 1.21, 95%
CI: 1.11–1.33; Table 2). In models adjusted for residual disease,
inactive women with high-grade serous and clear cell tumours
had significantly greater mortality than their active counterparts:
HR¼ 1.36 (95% CI: 1.17–1.58) and HR¼ 1.73 (95% CI: 1.06–2.84),
respectively (Table 3). Because we were insufficiently powered to
detect associations among the more infrequent histological
subtypes, we also limited histology classifications to serous vs
non-serous disease. Here we observed consistent evidence of the
association between inactivity and mortality for both tumour types,
both with and without adjustment for residual disease
(Supplementary Table S2).
In sensitivity analyses intended to reduce possible reverse
causation bias by exclusion of the three studies that assessed
inactivity only at enrollment, associations between inactivity and
mortality remained significant and were similar in magnitude to
the associations observed in our primary analysis: HR¼ 1.28 (95%
CI: 1.09–1.49) and HR¼ 1.19 (95% CI: 1.09–1.30) in models with
and without adjustment for residual disease, respectively. In
additional analyses excluding women who had died within 1 year
of diagnosis, the associations between inactivity and mortality
remained significant and of similar magnitude to those in primary
analyses in models both with (HR¼ 1.27, 95% CI: 1.10–1.47) and
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without (HR¼ 1.18, 95% CI: 1.08–1.29) adjustment for
residual disease. Finally, we observed no evidence of effect
modification of the association between inactivity and mortality
by tumour stage (Supplementary Table S3), menopausal status
(Supplementary Table S4), or overweight/obesity status
(Supplementary Table S5).
DISCUSSION
The current analyses of pooled individual-level data from OCAC
suggests that self-reported, habitual recreational physical inactivity
is an independent predictor of mortality among women diagnosed
Table 1. Characteristics of the Ovarian Cancer Association Consortium studies included in the analyses (N¼12 studies)
OCAC study namea
Study design
and source of
participants
Participant
ascertainment
Year of
diagnosis
Number of
participantsb
Median
(range) of
follow-up
time
(years)
Number (%)
deceased
(all follow-up
data)
Method of
follow-up
Australian Ovarian
Cancer Study/
Australian Cancer Study
(AUS) (Merritt et al,
2008)
Population-based
case–control
Cases obtained via
surgical treatment
centres and cancer
registries
2002–2006 1016 7.5 (10.0) 653 (64.3%) Medical record review
Connecticut Ovary
Study (CON) (Risch
et al, 2006)
Population-based
case–control
Cases obtained via
cancer registries and
pathology
departments
1998–2003 381 8.4 (10.4) 217 (57%) Connecticut Tumor
Registry and obituary
listings in Connecticut
newspapers
Diseases of the Ovary
and their Evaluation
(DOV) and (DVE)
(Rossing et al, 2007;
Bodelon et al, 2012)
Population-based
case–control
Cases identified via
SEER registry
2002–2009 884 4.4 (8.9) 350 (39.6%) Standard US NCI
SEER-registry follow-up
methods
Hawaii Ovarian Cancer
Case–Control Study
(HAW) (Goodman et al,
2008)
Population-based
case–control
Cases were
identified via cancer
registries
1993–2008 359 7.2 (16.5) 181 (50.4%) Standard US NCI
SEER-registry follow-up
methods and medical
record review
Hormones and Ovarian
Cancer Prediction
Study (HOP) (Lo-
Ciganic et al, 2012)
Population-based
case–control
Cases identified via
cancer registries,
physician offices,
and pathology
databases
2003–2008 506 5.1 (9.2) 262 (51.8%) Medical record review
and Social Security
database
Hospital-based
Research Program at
Aichi Cancer Center
(JPN) (Hamajima et al,
2001)
Hospital/Clinic-based
case-control
Cases identified via
cancer centre
database
2001–2005 51 5.0 (9.2) 21 (41.2%) Medical record review
Mayo Clinic Case-Only
Ovarian Cancer Study
(MAC) (Goode et al,
2011)
Hospital/clinic-based
case-only
Cases identified via
Mayo Clinic
Divisions of Surgical
Gynecology &
Medical Oncology
2000–2011 83 2.9 (16.2) 32 (38.6%) Patient contact and
vital statistics
MALignant OVArian
cancer (MAL) (Glud
et al, 2004)
Population-based
case–control
Cases identified via
cancer registry and
gynaecologic
departments
1994–1999 492 13.6 (16.0) 371 (75.4%) Danish Civil
Registration System
and Danish Register of
Causes of Death
Mayo Clinic Ovarian
Cancer Case-Control
Study (MAY) (Goode
et al, 2010; Kelemen
et al, 2010)
Hospital/clinic-based
case–control
Cases recruited from
Mayo Clinic
2000–2008 519 3.4 (8.9) 283 (54.5%) Patient contact and
vital statistics
New England Case
Control Study (NEC)
(Terry et al, 2005)
Population-based
case–control
Cases identified via
hospital tumour
boards and cancer
registries
1992–2008 785 13.4 (19.9) 454 (57.8%) Annual medical record
review and death
record database
New Jersey Ovarian
Cancer Study (NJO)
(Bandera et al, 2011)
Population-based
case–control
Cases identified via
New Jersey State
Cancer Registry
2004–2008 195 6.4 (11.2) 110 (56.4%) Linkage with the New
Jersey State Cancer
Registry
Los Angeles County
Case–Control Studies
of Ovarian Cancer-1 &
2 (USC) (Wu et al, 2015)
Population-based
case–control
Cases identified via
LA County Cancer
Surveillance Program
1993–2009 1535 8.3 (18.0) 823 (53.6%) Standard US NCI
SEER-registry follow-
up methods
Abbreviation: OCAC¼Ovarian Cancer Association Consortium.
aStudy sites are listed in alphabetical order by OCAC study abbreviation.
bTotal participant numbers reflect invasive cases in the OCAC core data set (July 2014) with available vital status and recreational physical activity data.
Physical inactivity and ovarian cancer mortality BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.153 97
with invasive EOC. The observed associations between inactivity
and mortality were consistently seen in sensitivity analyses
designed to reduce potential biases and were robust to adjustment
for relevant confounders and well-established prognostic factors.
Importantly, physical inactivity remained an independent pre-
dictor of mortality even among participants diagnosed with
advanced disease. If the association with pre-diagnostic activity
also applies to physical activity after ovarian cancer diagnosis,
it is possible that targeted intervention to reduce inactivity,
adjuvant to medical management, could improve survival in
women with EOC. This association needs confirmation by a large
randomised trial.
Several biological mechanisms have been proposed to account
for an association between physical inactivity and cancer develop-
ment, including increased adiposity, increased circulating sex
hormones, chronic inflammation, impaired immune surveillance,
impaired insulin regulation, and dysregulated adipokines
(McTiernan, 2008). These same mechanisms could explain some
of the observed mortality risks associated with physical inactivity in
cancer survivors (Li et al, 2016). Further, obesity and physical
inactivity may affect carcinogenesis through independent pathways
(Byers, 2014; Hildebrand et al, 2015; Sanchis-Gomar et al, 2015).
Our finding of significantly increased mortality among inactive
women with diagnosed EOC supports this hypothesis. We
Table 2. Hazard ratios and 95% confidence intervals representing the association between recreational physical inactivity and
mortality among women diagnosed with invasive EOC (N¼6806; 12 studies)a
95% CI
EOC histology Modelb N (events) N (censored) HR Lower Upper P-value
All EOC casesc Age-adjusted 2898 3907 1.13 1.04 1.22 0.005
Multivariable 2861 3876 1.22 1.12 1.33 o0.001
Invasive high-grade serousd Age-adjusted 2287 1902 1.16 1.05 1.27 0.002
Multivariable 2281 1900 1.21 1.11 1.33 o0.001
Invasive low-grade serousd Age-adjusted 104 213 1.16 0.77 1.75 0.479
Multivariable 103 213 1.30 0.89 1.96 0.219
Invasive mucinousd Age-adjusted 85 380 1.21 0.77 1.91 0.410
Multivariable 85 379 0.93 0.59 1.49 0.773
Invasive endometrioidd Age-adjusted 225 943 1.14 0.85 1.53 0.395
Multivariable 225 943 1.26 0.94 1.70 0.125
Invasive clear celld Age-adjusted 167 441 1.30 0.93 1.80 0.125
Multivariable 167 441 1.29 0.92 1.79 0.136
Abbreviations: CI¼ confidence interval; EOC¼ epithelial ovarian cancer; HR¼ hazard ratio.
aNumbers may not sum to total due to missing data.
bAdjustment variables were identified based on well-established prognostic factors for EOC and the 10% change-in-estimate method.
cMultivariable model is adjusted for age, stage, and histotype.
dMultivariable model is adjusted for age and stage.
Table 3. Residual disease-adjusted hazard ratiosa and 95% confidence intervals representing the association between
recreational physical inactivity and mortality among women diagnosed with invasive EOC (N¼2473; 7 studies)b
95% CI
EOC histology Modelc N (events) N (censored) HR Lower Upper P-value
All EOC casesd Age-adjusted 1057 1135 1.28 1.13 1.46 o0.001
Multivariable #1 1055 1135 1.40 1.23 1.60 o0.001
Multivariable #2 1055 1135 1.34 1.18 1.52 o0.001
Invasive high-grade serouse Age-adjusted 827 579 1.36 1.18 1.58 o0.001
Multivariable #1 826 579 1.41 1.22 1.64 o0.001
Multivariable #2 826 579 1.35 1.17 1.57 o0.001
Invasive low-grade serouse Age-adjusted 61 80 0.90 0.54 1.51 0.698
Multivariable #1 60 80 1.14 0.68 1.92 0.611
Multivariable #2 60 80 0.90 0.53 1.52 0.684
Invasive mucinouse Age-adjusted 28 102 1.75 0.83 3.71 0.145
Multivariable #1 28 102 1.27 0.59 2.72 0.538
Multivariable #2 28 102 1.14 0.52 2.46 0.749
Invasive endometrioide Age-adjusted 76 249 1.25 0.78 2.03 0.356
Multivariable #1 76 249 1.17 0.73 1.90 0.514
Multivariable #2 76 249 1.09 0.67 1.77 0.720
Invasive clear celle Age-adjusted 65 125 1.73 1.06 2.84 0.029
Multivariable #1 65 125 1.64 1.00 2.67 0.050
Multivariable #2 65 125 1.73 1.06 2.84 0.029
Abbreviations: CI¼ confidence interval; EOC¼ epithelial ovarian cancer; HR¼ hazard ratio.
aHazard ratios represent mortality among participants with available residual disease data from seven studies (AUS, HAW, JPN, MAC, MAL, MAY, and NEC).
bNumbers may not sum to total due to missing data.
cAdjustment variables were identified based on well-established prognostic factors for EOC and the 10% change-in-estimate method.
dMultivariable model #1 is adjusted for age, stage, and histotype; multivariable model #2 is adjusted for age, stage, histotype, and residual disease.
eMultivariable model #1 is adjusted for age and stage; multivariable model #2 is adjusted for age, stage, and residual disease.
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observed no appreciable evidence that this association was
confounded or modified by BMI, supporting further investigation
of the role that physical inactivity may have in preventing EOC or
improving its survivability.
A strength of our study is that our analyses were conducted with
individual-level data from well-designed epidemiological investiga-
tions. Our ability to adjust for established prognostic factors
decreased the chance that the observed associations were explained
by confounding. Further, the observed associations remained
significant in sensitivity analyses designed to reduce sources of
bias. On the other hand, potential measurement error associated
with self-reported inactivity data categorised dichotomously is an
important limitation. However, using physical inactivity as the
exposure variable likely involves less exposure misclassification
than would occur with categorised incremental physical activity
exposures, and such misclassification would likely be non-
differential with respect to vital status, thus tending to bias
observed associations toward the null.
In summary, our findings add to a growing body of literature
suggesting that physical inactivity is associated with unfavourable
health outcomes, including poorer cancer outcomes. Given the
global epidemic of physical inactivity, these findings have
important public health and clinical implications, particularly in
the context of a lack of modifiable prognostic factors for EOC, and
only modest improvements in survival among women diagnosed
with EOC in recent decades (SEER, 2014). Well-designed
prospective studies are needed to confirm the survival benefit
and to assess how much mortality can be reduced among women
diagnosed with invasive EOC.
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